Growth hormone secretagogues (GHS) represent one of the most actively studied classes of research peptides in modern endocrinology. Among them, ipamorelin and GHRP-6 stand out as two of the most widely referenced compounds in preclinical and early clinical literature. Both bind the growth hormone secretagogue receptor (GHS-R1a) to stimulate endogenous growth hormone (GH) release, yet they differ meaningfully in selectivity, off-target hormonal effects, and downstream research utility.
This article examines the published evidence comparing ipamorelin and GHRP-6 across receptor pharmacology, potency, safety profiles, and current research applications. All compounds discussed are for research purposes only and are not intended for human or animal use.
Receptor Pharmacology: GHS-R1a and Beyond
Both ipamorelin and GHRP-6 exert their primary effects through activation of GHS-R1a, a seven-transmembrane G protein-coupled receptor expressed in the anterior pituitary, hypothalamus, heart, and several other tissues. When activated, GHS-R1a signals through Gq proteins, triggering phospholipase C (PLC) activation, inositol trisphosphate (IP3) generation, and intracellular calcium mobilization—the calcium surge that drives GH granule release from somatotroph cells (Smith et al., 2007).
Where the two peptides diverge is in their broader receptor engagement. GHRP-6 (His-DTrp-Ala-Trp-DPhe-Lys-NH2) binds not only GHS-R1a but also CD36, a scavenger receptor involved in fatty acid transport and inflammatory signaling. This dual receptor binding activates prosurvival pathways such as PI-3K/AKT1, contributing to the cytoprotective effects observed in cardiac and gastrointestinal tissue models (Berlanga-Acosta et al., 2017).
Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH2), a synthetic pentapeptide developed by Novo Nordisk in the late 1990s, appears to stabilize a GHS-R1a conformation that couples efficiently to GH-releasing pathways in somatotrophs while coupling poorly to pathways in corticotrophs and lactotrophs. This concept—known as biased agonism or functional selectivity—helps explain its remarkably clean hormonal profile (Raun et al., 1998).
All peptides discussed in this article are sold strictly for research purposes only. These products are not intended for human consumption, therapeutic use, or any application other than in vitro and preclinical laboratory research.
In conscious swine models, the landmark 1998 study by Raun et al. established that ipamorelin releases GH with an ED50 of 2.3 nmol/kg and a maximal efficacy (Emax) of 65 ng GH/mL plasma. GHRP-6 demonstrated comparable potency with an ED50 of 3.9 nmol/kg and Emax of 74 ng GH/mL plasma. These data suggest that, at equipotent doses, both peptides achieve similar peak GH output.
However, potency alone does not tell the full story. GHRP-2, a structural analog of GHRP-6, has been shown to produce a 47-fold increase in pulsatile GH secretion in some models, compared to GHRH alone at 20-fold—and combining GHRH with GHRP-2 yields a 54-fold increase (Sinha et al., 2020). This synergistic potential between GHRH-pathway and GHRP-pathway compounds has driven interest in combination research protocols, such as CJC-1295/Ipamorelin blends, which activate complementary signaling cascades.
Half-Life and Metabolic Stability
Ipamorelin’s modified amino acid backbone (incorporating aminoisobutyric acid) provides enhanced resistance to peptidase degradation compared to GHRP-6’s native amino acid structure. This translates to a longer effective window in research models, potentially reducing the frequency of administration required in sustained-release study designs.
The Selectivity Advantage: Cortisol, Prolactin, and ACTH
The defining characteristic that separates ipamorelin from virtually every other growth hormone secretagogue is its hormonal selectivity. In the foundational study by Raun et al. (1998), administration of GHRP-6 and GHRP-2 both resulted in significant increases in plasma ACTH and cortisol levels. Ipamorelin, by contrast, did not elevate ACTH or cortisol at levels meaningfully different from GHRH stimulation alone—even at doses exceeding 200 times the ED50 for GH release.
Neither compound significantly affected FSH, LH, PRL, or TSH levels, though GHRP-6 has demonstrated dose-dependent prolactin elevation (+15–60%) and cortisol elevation (+10–50%) at higher research doses (Sigalos & Pastuszak, 2018).
This selectivity profile makes ipamorelin the preferred secretagogue in research protocols where investigators need to isolate GH-specific effects without confounding variables from adrenal or lactotroph axis activation.
Disclaimer: These compounds are intended for laboratory research only. Nothing in this article should be interpreted as medical advice or an endorsement of use in humans or animals.
Research Applications: Where Each Peptide Excels
Ipamorelin: Skeletal, Gastrointestinal, and Metabolic Research
Preclinical studies have established several active research areas for ipamorelin:
Bone biology: Johansen et al. (1999) demonstrated dose-dependent increases in longitudinal bone growth rate in adult female rats. Svensson et al. (2000) confirmed that both ipamorelin and GHRP-6 increase bone mineral content, with effects attributed to increased bone dimensions rather than density changes per se.
Gastrointestinal motility: Ipamorelin has been studied as a prokinetic agent in postoperative ileus models. Venkova et al. (2009) showed that repetitive dosing significantly increased cumulative fecal output, food intake, and body weight recovery in rodent models. Greenwood-Van Meerveld et al. (2012) demonstrated that ipamorelin accelerated gastric emptying through ghrelin receptor-mediated cholinergic excitatory neuron activation.
Clinical investigation: A Phase 2 proof-of-concept trial (Beck et al., 2014) evaluated ipamorelin for postoperative ileus management in 114 bowel resection patients, finding the compound well-tolerated though without statistically significant efficacy differences versus placebo.
GHRP-6: Cardioprotection, Cytoprotection, and Appetite Research
GHRP-6’s broader receptor engagement opens distinct research avenues:
Cardioprotection: In a porcine acute myocardial infarction model, GHRP-6 reduced infarct mass by 78% and preserved wall thickness by 50% compared to saline controls (Berlanga-Acosta et al., 2017). A 2024 study further demonstrated that GHRP-6 prevents doxorubicin-induced cardiotoxicity through activation of PI3K/AKT prosurvival mechanisms (Berlanga-Acosta et al., 2024).
Neuroprotection: Combined EGF and GHRP-6 therapy has shown neuroprotective effects comparable to hypothermia in experimental stroke models. A Phase I/II clinical trial (Hernandez-Bernal et al., 2024) evaluated this combination in acute ischemic stroke patients, reporting acceptable safety and supporting advancement to Phase III investigation.
Appetite and cachexia models: GHRP-6 produces robust appetite stimulation beginning 20–30 minutes post-administration and lasting 1–3 hours (Yahashi et al., 2012). This pronounced ghrelin-mimetic effect makes GHRP-6 particularly valuable in cachexia, wasting syndrome, and appetite-disorder research models.
Gastroprotection: A single prophylactic administration of GHRP-6 has been shown to prevent Curling-like stress ulcers in conscious rats through a dual mechanism: direct activation of survival signaling in gastric epithelial cells and simultaneous blunting of vagal efferent function (Berlanga-Acosta et al., 2017).
Head-to-Head Comparison Table
Parameter
Ipamorelin
GHRP-6
Structure
Pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2)
Hexapeptide (His-DTrp-Ala-Trp-DPhe-Lys-NH2)
GH Release ED50
2.3 nmol/kg (swine)
3.9 nmol/kg (swine)
Cortisol Effect
No elevation (even at 200x ED50)
Dose-dependent elevation (+10–50%)
Prolactin Effect
No significant change
Dose-dependent elevation (+15–60%)
Appetite Stimulation
Minimal
Pronounced (20–30 min onset)
Receptor Targets
GHS-R1a (selective)
GHS-R1a + CD36
Key Research Areas
Bone growth, GI motility, clean GH studies
Cardioprotection, neuroprotection, cachexia
Choosing the Right Compound for Your Research
The choice between ipamorelin and GHRP-6 depends entirely on the research question at hand. When investigators need to study GH-dependent pathways in isolation—without cortisol, ACTH, or prolactin confounders—ipamorelin is the logical choice. Its clean selectivity profile simplifies experimental design and data interpretation.
When the research model benefits from broader receptor engagement—such as cardioprotection studies, cytoprotective mechanism investigations, or appetite-regulation research—GHRP-6 offers unique pharmacological tools that ipamorelin cannot replicate.
For researchers exploring synergistic GH release, combining a GHRP-pathway compound with a GHRH-pathway analog like sermorelin or CJC-1295 can produce amplified responses through complementary signaling cascades. Oath Research provides third-party lab-tested certificates for all research compounds to support reproducible experimental outcomes.
All products sold by Oath Research are intended for in vitro and preclinical research only. They are not approved for human or animal use, and nothing on this page constitutes medical advice.
What is the primary difference between ipamorelin and GHRP-6?
The most significant distinction is selectivity. Ipamorelin stimulates growth hormone release without elevating cortisol, ACTH, or prolactin, while GHRP-6 produces dose-dependent increases in these hormones alongside GH release. Ipamorelin has been described as the first growth hormone secretagogue with selectivity comparable to GHRH itself (Raun et al., 1998).
Which compound produces stronger growth hormone release?
In preclinical swine models, both peptides achieve comparable peak GH output. Ipamorelin demonstrated an ED50 of 2.3 nmol/kg versus 3.9 nmol/kg for GHRP-6, suggesting slightly higher potency per unit dose for ipamorelin, though maximal GH levels were similar between the two compounds.
Why does GHRP-6 stimulate appetite while ipamorelin does not?
GHRP-6 is a potent ghrelin mimetic that activates hypothalamic neuropeptide Y (NPY) and agouti-related peptide (AgRP) pathways—key drivers of appetite signaling. Ipamorelin, through its biased agonism at GHS-R1a, appears to couple preferentially to GH-releasing pathways without strongly engaging the appetite-regulating circuits.
Can ipamorelin and GHRP-6 be combined in research protocols?
While both target GHS-R1a, combination research more commonly pairs a GHRP-pathway compound (ipamorelin or GHRP-6) with a GHRH-pathway analog (such as CJC-1295 or sermorelin) to achieve synergistic GH release through complementary receptor mechanisms.
What are the main research applications for GHRP-6 beyond growth hormone release?
GHRP-6 has demonstrated cardioprotective effects (reducing infarct size by up to 78% in animal models), neuroprotective properties when combined with EGF in stroke research, gastroprotective activity against stress-induced ulceration, and significant appetite stimulation useful in cachexia and wasting-syndrome models.
Has ipamorelin been studied in any clinical trials?
Yes. A Phase 2 proof-of-concept trial evaluated ipamorelin for postoperative ileus management in 114 bowel resection patients. The compound was well-tolerated, and the ipamorelin group showed a numerically faster median time to tolerating solid food (25.3 vs. 32.6 hours), though the primary endpoint did not reach statistical significance (Beck et al., 2014).
Are these peptides available for research purposes?
Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PubMed
Johansen PB, Nowak J, Skjaerbaek C, et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999;9(2):106-113. PubMed
Svensson J, Lall S, Dickson SL, et al. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. J Endocrinol. 2000;165(3):569-577. PubMed
Smith RG, Sun Y, Jiang H, et al. Ghrelin receptor (GHS-R1A) agonists show potential as interventive agents during aging. Ann N Y Acad Sci. 2007;1119:147-164. PubMed
Venkova K, Mann W, Nelson R, Greenwood-Van Meerveld B. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. J Pharmacol Exp Ther. 2009;329(3):1110-1116. PubMed
Greenwood-Van Meerveld B, Tyler K, Mohammadi E, Pietra C. Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus. J Exp Pharmacol. 2012;4:149-155. PubMed
Yahashi S, Kang KS, Kaiya H, Matsuda K. GHRP-6 mimics ghrelin-induced stimulation of food intake and suppression of locomotor activity in goldfish. Peptides. 2012;34(2):324-328. PubMed
Hassouna R, Labarthe A, Zizzari P, et al. Actions of agonists and antagonists of the ghrelin/GHS-R pathway on GH secretion, appetite, and cFos activity. Front Endocrinol. 2013;4:25. PubMed
Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014;29(12):1527-1534. PubMed
Berlanga-Acosta J, Abreu-Cruz A, Garcia-del Barco Herrera D, et al. Synthetic growth hormone-releasing peptides (GHRPs): a historical appraisal of the evidences supporting their cytoprotective effects. Clin Med Insights Cardiol. 2017;11:1179546817694558. PubMed
Sigalos JT, Pastuszak AW. The safety and efficacy of growth hormone secretagogues. Sex Med Rev. 2018;6(1):45-53. PubMed
Sinha DK, Balasubramanian A, Tatem AJ, et al. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol. 2020;9(Suppl 2):S149-S159. PubMed
Berlanga-Acosta J, Cibrian D, Valiente-Mustelier J, et al. Growth hormone releasing peptide-6 (GHRP-6) prevents doxorubicin-induced myocardial and extra-myocardial damages by activating prosurvival mechanisms. Front Pharmacol. 2024;15:1402138. PubMed
Hernandez-Bernal F, Estenoz-Garcia D, Gutierrez-Ronquillo JH, et al. Combination therapy of epidermal growth factor and growth hormone-releasing hexapeptide in acute ischemic stroke: a phase I/II non-blinded, randomized clinical trial. Front Neurol. 2024;15:1303402. PubMed
Tesamorelin occupies a unique position in peptide therapeutics as one of the few synthetic growth hormone-releasing hormone (GHRH) analogs to receive FDA approval. For researchers and clinicians working with growth hormone therapies, understanding tesamorelin’s regulatory status, approved applications, and the evidence supporting its authorization provides essential context for evaluating its role in treatment protocols. Updated …
Discover how the Selank and Semax nootropic stack uniquely combines two powerful peptides to boost cognitive function, reduce anxiety, and elevate your brain health for peak mental performance.
Ipamorelin vs. GHRP-6: Selectivity, Potency, and Research Applications
Introduction: Two Paths to Growth Hormone Release
Growth hormone secretagogues (GHS) represent one of the most actively studied classes of research peptides in modern endocrinology. Among them, ipamorelin and GHRP-6 stand out as two of the most widely referenced compounds in preclinical and early clinical literature. Both bind the growth hormone secretagogue receptor (GHS-R1a) to stimulate endogenous growth hormone (GH) release, yet they differ meaningfully in selectivity, off-target hormonal effects, and downstream research utility.
This article examines the published evidence comparing ipamorelin and GHRP-6 across receptor pharmacology, potency, safety profiles, and current research applications. All compounds discussed are for research purposes only and are not intended for human or animal use.
Receptor Pharmacology: GHS-R1a and Beyond
Both ipamorelin and GHRP-6 exert their primary effects through activation of GHS-R1a, a seven-transmembrane G protein-coupled receptor expressed in the anterior pituitary, hypothalamus, heart, and several other tissues. When activated, GHS-R1a signals through Gq proteins, triggering phospholipase C (PLC) activation, inositol trisphosphate (IP3) generation, and intracellular calcium mobilization—the calcium surge that drives GH granule release from somatotroph cells (Smith et al., 2007).
Where the two peptides diverge is in their broader receptor engagement. GHRP-6 (His-DTrp-Ala-Trp-DPhe-Lys-NH2) binds not only GHS-R1a but also CD36, a scavenger receptor involved in fatty acid transport and inflammatory signaling. This dual receptor binding activates prosurvival pathways such as PI-3K/AKT1, contributing to the cytoprotective effects observed in cardiac and gastrointestinal tissue models (Berlanga-Acosta et al., 2017).
Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH2), a synthetic pentapeptide developed by Novo Nordisk in the late 1990s, appears to stabilize a GHS-R1a conformation that couples efficiently to GH-releasing pathways in somatotrophs while coupling poorly to pathways in corticotrophs and lactotrophs. This concept—known as biased agonism or functional selectivity—helps explain its remarkably clean hormonal profile (Raun et al., 1998).
All peptides discussed in this article are sold strictly for research purposes only. These products are not intended for human consumption, therapeutic use, or any application other than in vitro and preclinical laboratory research.
$99.99Original price was: $99.99.$95.00Current price is: $95.00.Potency: How Do They Compare in GH Release?
In conscious swine models, the landmark 1998 study by Raun et al. established that ipamorelin releases GH with an ED50 of 2.3 nmol/kg and a maximal efficacy (Emax) of 65 ng GH/mL plasma. GHRP-6 demonstrated comparable potency with an ED50 of 3.9 nmol/kg and Emax of 74 ng GH/mL plasma. These data suggest that, at equipotent doses, both peptides achieve similar peak GH output.
However, potency alone does not tell the full story. GHRP-2, a structural analog of GHRP-6, has been shown to produce a 47-fold increase in pulsatile GH secretion in some models, compared to GHRH alone at 20-fold—and combining GHRH with GHRP-2 yields a 54-fold increase (Sinha et al., 2020). This synergistic potential between GHRH-pathway and GHRP-pathway compounds has driven interest in combination research protocols, such as CJC-1295/Ipamorelin blends, which activate complementary signaling cascades.
Half-Life and Metabolic Stability
Ipamorelin’s modified amino acid backbone (incorporating aminoisobutyric acid) provides enhanced resistance to peptidase degradation compared to GHRP-6’s native amino acid structure. This translates to a longer effective window in research models, potentially reducing the frequency of administration required in sustained-release study designs.
The Selectivity Advantage: Cortisol, Prolactin, and ACTH
The defining characteristic that separates ipamorelin from virtually every other growth hormone secretagogue is its hormonal selectivity. In the foundational study by Raun et al. (1998), administration of GHRP-6 and GHRP-2 both resulted in significant increases in plasma ACTH and cortisol levels. Ipamorelin, by contrast, did not elevate ACTH or cortisol at levels meaningfully different from GHRH stimulation alone—even at doses exceeding 200 times the ED50 for GH release.
Neither compound significantly affected FSH, LH, PRL, or TSH levels, though GHRP-6 has demonstrated dose-dependent prolactin elevation (+15–60%) and cortisol elevation (+10–50%) at higher research doses (Sigalos & Pastuszak, 2018).
This selectivity profile makes ipamorelin the preferred secretagogue in research protocols where investigators need to isolate GH-specific effects without confounding variables from adrenal or lactotroph axis activation.
Disclaimer: These compounds are intended for laboratory research only. Nothing in this article should be interpreted as medical advice or an endorsement of use in humans or animals.
Research Applications: Where Each Peptide Excels
Ipamorelin: Skeletal, Gastrointestinal, and Metabolic Research
Preclinical studies have established several active research areas for ipamorelin:
Bone biology: Johansen et al. (1999) demonstrated dose-dependent increases in longitudinal bone growth rate in adult female rats. Svensson et al. (2000) confirmed that both ipamorelin and GHRP-6 increase bone mineral content, with effects attributed to increased bone dimensions rather than density changes per se.
Gastrointestinal motility: Ipamorelin has been studied as a prokinetic agent in postoperative ileus models. Venkova et al. (2009) showed that repetitive dosing significantly increased cumulative fecal output, food intake, and body weight recovery in rodent models. Greenwood-Van Meerveld et al. (2012) demonstrated that ipamorelin accelerated gastric emptying through ghrelin receptor-mediated cholinergic excitatory neuron activation.
Clinical investigation: A Phase 2 proof-of-concept trial (Beck et al., 2014) evaluated ipamorelin for postoperative ileus management in 114 bowel resection patients, finding the compound well-tolerated though without statistically significant efficacy differences versus placebo.
$99.99Original price was: $99.99.$95.00Current price is: $95.00.GHRP-6: Cardioprotection, Cytoprotection, and Appetite Research
GHRP-6’s broader receptor engagement opens distinct research avenues:
Cardioprotection: In a porcine acute myocardial infarction model, GHRP-6 reduced infarct mass by 78% and preserved wall thickness by 50% compared to saline controls (Berlanga-Acosta et al., 2017). A 2024 study further demonstrated that GHRP-6 prevents doxorubicin-induced cardiotoxicity through activation of PI3K/AKT prosurvival mechanisms (Berlanga-Acosta et al., 2024).
Neuroprotection: Combined EGF and GHRP-6 therapy has shown neuroprotective effects comparable to hypothermia in experimental stroke models. A Phase I/II clinical trial (Hernandez-Bernal et al., 2024) evaluated this combination in acute ischemic stroke patients, reporting acceptable safety and supporting advancement to Phase III investigation.
Appetite and cachexia models: GHRP-6 produces robust appetite stimulation beginning 20–30 minutes post-administration and lasting 1–3 hours (Yahashi et al., 2012). This pronounced ghrelin-mimetic effect makes GHRP-6 particularly valuable in cachexia, wasting syndrome, and appetite-disorder research models.
Gastroprotection: A single prophylactic administration of GHRP-6 has been shown to prevent Curling-like stress ulcers in conscious rats through a dual mechanism: direct activation of survival signaling in gastric epithelial cells and simultaneous blunting of vagal efferent function (Berlanga-Acosta et al., 2017).
Head-to-Head Comparison Table
Choosing the Right Compound for Your Research
The choice between ipamorelin and GHRP-6 depends entirely on the research question at hand. When investigators need to study GH-dependent pathways in isolation—without cortisol, ACTH, or prolactin confounders—ipamorelin is the logical choice. Its clean selectivity profile simplifies experimental design and data interpretation.
When the research model benefits from broader receptor engagement—such as cardioprotection studies, cytoprotective mechanism investigations, or appetite-regulation research—GHRP-6 offers unique pharmacological tools that ipamorelin cannot replicate.
For researchers exploring synergistic GH release, combining a GHRP-pathway compound with a GHRH-pathway analog like sermorelin or CJC-1295 can produce amplified responses through complementary signaling cascades. Oath Research provides third-party lab-tested certificates for all research compounds to support reproducible experimental outcomes.
All products sold by Oath Research are intended for in vitro and preclinical research only. They are not approved for human or animal use, and nothing on this page constitutes medical advice.
$99.99Original price was: $99.99.$95.00Current price is: $95.00.Frequently Asked Questions
What is the primary difference between ipamorelin and GHRP-6?
The most significant distinction is selectivity. Ipamorelin stimulates growth hormone release without elevating cortisol, ACTH, or prolactin, while GHRP-6 produces dose-dependent increases in these hormones alongside GH release. Ipamorelin has been described as the first growth hormone secretagogue with selectivity comparable to GHRH itself (Raun et al., 1998).
Which compound produces stronger growth hormone release?
In preclinical swine models, both peptides achieve comparable peak GH output. Ipamorelin demonstrated an ED50 of 2.3 nmol/kg versus 3.9 nmol/kg for GHRP-6, suggesting slightly higher potency per unit dose for ipamorelin, though maximal GH levels were similar between the two compounds.
Why does GHRP-6 stimulate appetite while ipamorelin does not?
GHRP-6 is a potent ghrelin mimetic that activates hypothalamic neuropeptide Y (NPY) and agouti-related peptide (AgRP) pathways—key drivers of appetite signaling. Ipamorelin, through its biased agonism at GHS-R1a, appears to couple preferentially to GH-releasing pathways without strongly engaging the appetite-regulating circuits.
Can ipamorelin and GHRP-6 be combined in research protocols?
While both target GHS-R1a, combination research more commonly pairs a GHRP-pathway compound (ipamorelin or GHRP-6) with a GHRH-pathway analog (such as CJC-1295 or sermorelin) to achieve synergistic GH release through complementary receptor mechanisms.
What are the main research applications for GHRP-6 beyond growth hormone release?
GHRP-6 has demonstrated cardioprotective effects (reducing infarct size by up to 78% in animal models), neuroprotective properties when combined with EGF in stroke research, gastroprotective activity against stress-induced ulceration, and significant appetite stimulation useful in cachexia and wasting-syndrome models.
Has ipamorelin been studied in any clinical trials?
Yes. A Phase 2 proof-of-concept trial evaluated ipamorelin for postoperative ileus management in 114 bowel resection patients. The compound was well-tolerated, and the ipamorelin group showed a numerically faster median time to tolerating solid food (25.3 vs. 32.6 hours), though the primary endpoint did not reach statistical significance (Beck et al., 2014).
Are these peptides available for research purposes?
Yes. Both ipamorelin and GHRP-6 are available from Oath Research as research-grade compounds with third-party certificates of analysis verifying identity and purity.
References
2 Day FAST Shipping
99%+ Purity Tests
Ships from Gilbert Arizona
USA Lab Tested
Free bacteriostatic water with every order.
Related Posts
Is Tesamorelin FDA Approved? Current Status
Tesamorelin occupies a unique position in peptide therapeutics as one of the few synthetic growth hormone-releasing hormone (GHRH) analogs to receive FDA approval. For researchers and clinicians working with growth hormone therapies, understanding tesamorelin’s regulatory status, approved applications, and the evidence supporting its authorization provides essential context for evaluating its role in treatment protocols. Updated …
Selank and Semax Research: Nootropic Peptide Science (56 chars)
Discover how the Selank and Semax nootropic stack uniquely combines two powerful peptides to boost cognitive function, reduce anxiety, and elevate your brain health for peak mental performance.